This website contains forward-looking statements under the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements about BioSante´s plans, objectives, expectations and intentions with respect to future operations and products, BioSante´s future burn rate and the sufficiency of its cash and cash equivalents, and other statements identified by words such as "will," "continue," "could," "believes," "intends," "expects," "estimates," "anticipates," "plans," "may," "potential," "projected," other words of similar meaning, derivations of such words and the use of future dates. Forward-looking statements by their nature address matters that are, to different degrees, uncertain. Uncertainties and risks may cause BioSante´s actual results to be materially different than those expressed in or implied by BioSante’s forward-looking statements. For BioSante, particular uncertainties and risks include, among others, the difficulty of developing pharmaceutical products, obtaining regulatory and other approvals and achieving market acceptance; the uncertainties of clinical testing, the marketing success of BioSante´s licensees or sublicensees and BioSante´s future revenues, if any, from its licensees and sublicensees; uncertainties relating to the future and costs of BioSante´s product development programs and its need for and ability to obtain additional financing. More detailed information on these and additional factors that could affect BioSante´s actual results are described in BioSante´s filings with the Securities and Exchange Commission, including its most recent annual report on Form 10-K and subsequent quarterly reports on Form 10-Q. The information posted on this website is as of the date indicated and, to our knowledge, was timely and accurate when posted. We are under no obligation to update, revise or remove outdated information, including forward-looking statements, whether as a result of new information, future events or otherwise.